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Highlights of primary biliary cirrhosis
Primary biliary cirrhosis (PBC) is an autoimmune chronic 
cholestatic  liver  disease,  histopathologically  charac­
terized  by  portal  inflammation  and  immune­mediated 
destruction  of  the  intrahepatic  bile  ducts  within  the 
portal tracts and epithelioid granulomas around damaged 
bile ducts. The loss of bile ducts leads to decreased bile 
secretion and the retention of toxic substances within the 
liver,  resulting  in  further  hepatic  damage,  fibrosis, 
cirrhosis  and,  eventually,  liver  failure  [1].  Serologically, 
PBC  is  characterized  by  the  presence  of  antimito­
chondrial antibodies (AMAs) ­which are present in 90 to 
95%  of  patients  and  are  often  detectable  years  before 
clinical signs appear [2]; high plasma levels of immuno­
globulin M (IgM) [3]; and high­titer antibodies against 
nuclear antigens (ANAs). It is estimated that 30 to 50% of 
patients also have specific ANAs, including antibodies to 
nucleoporin p62 (Nup62), a glycoprotein located within 
the nuclear pore complex (NPC) [4]. These antibodies are 
associated with more severe forms of the disease. While 
AMA  presence  is  often  used  for  diagnostic  purposes, 
ANAs and Nup62 could be linked to prognosis and are 
helpful tools in the management of patients with PBC, 
particularly in the AMA­negative subgroup [5,6].
PBC  primarily  affects  middle­aged  women,  with  a 
female/male ratio of 9/1, a characteristic shared by other 
autoimmune  diseases  [7].  It  also  seems  to  be  more 
common  among  the  first­degree  relatives  of  patients 
[8,9]. Studies of the annual incidence and prevalence of 
PBC in different geographical areas suggest the impact of 
ethnic  influences,  environmental  factors  and  the  non­
uniform criteria used for the diagnosis of PBC. PBC still 
appears to be more frequent in northern Europe and the 
United States, but overall the incidence ranges between 
0.7 and 49 per million population, while the prevalence is 
between 6.7 and 402 cases per million population [10], 
thus making PBC a rare disease according to the 2002 
Rare Disease Act. Several studies have reported a sub­
stantial increase in PBC prevalence and incidence over 
recent  decades,  similar  to  other  autoimmune  diseases 
[11]. This is mostly due to a better and earlier recognition 
of disease, and to more sensitive diagnostic procedures 
[12].  PBC  is  now  diagnosed  at  an  earlier  stage  in  its 
clinical course than it was in the past, with 50 to 60% of 
patients  asymptomatic  at  diagnosis,  and  one­third  of 
them remaining symptom free for many years.
The  diagnosis  of  PBC  is  currently  based  on  three 
criteria:  serological  positivity  for  AMA,  a  cholestatic 
biochemical picture with elevated levels of serum alkaline 
phosphatase and γ glutamyl transferase lasting for over 
6 months, and histological features compatible with the 
presence of the disease. A probable diagnosis requires the 
presence  of  two  of  these  three  criteria,  and  a  definite 
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Primary biliary cirrhosis (PBC) is an autoimmune 
hepatobiliary disease characterized by immune-
mediated injury of small and medium-sized bile 
ducts, eventually leading to liver cirrhosis. Several 
studies have addressed PBC immunopathology, and 
the data support an immune activation leading to 
autoantibodies and autoreactive T cells acting against 
the lipoylated 2-oxoacid dehydrogenase complexes. 
The causes of the disease remain unknown, but 
environmental factors and genetic susceptibility both 
contribute to its onset. Over the past two decades 
several association studies have addressed the role 
of genetic polymorphisms in PBC pathogenesis and 
have reported multiple associations. However, only 
a few studies had sufficient statistical power, and in 
most cases results were not independently validated. 
A genome-wide association study has recently 
been reported, but this too awaits independent 
confirmation. The aim of this present work is to 
critically review the numerous studies dedicated to 
revealing genetic associations in PBC, and to predict 
the potential for future studies based on these data.
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compatible  liver  biopsy  together  with  biochemical 
cholestatic features of PBC but in the absence of AMA is 
seen. This connotes the condition known as AMA­nega­
tive  PBC  or  ‘autoimmune  cholangiopathy’,  now  con­
sidered a nosological entity, practically identical to PBC 
apart from the serological profile [13,14]. From a clinical 
standpoint,  PBC  can  be  divided  into  four  stages:  pre­
sympto  matic (characterized by AMA seropositivity with 
abnormal liver tests and without symptoms), asymp  to­
matic  (AMA  seropositivity  and  abnormal  liver  tests), 
symptomatic (patients present PBC­related symptoms), 
and  decompensated  (symptoms  and  complications  of 
end­stage liver disease).
The  natural  history  of  PBC  is  characteristically 
associated with important variations: while some patients 
present with a slowly progressive disease, others have an 
early onset of complications. A recent case­control study 
[15] showed not only that PBC is associated with other 
autoimmune  diseases  in  30%  of  cases  (Raynaud’s  syn­
drome  in  12%,  Sjögren  syndrome  in  10%,  rheumatoid 
arthritis  in  10%,  autoimmune  thyroid  disease  in  9%, 
systemic  lupus  erythematosus  (SLE)  in  3%  and  sclero­
derma in 2% of cases), but also that this association may be 
considered a negative prognostic factor. Finally, although 
several  studies  have  suggested  that  the  early  use  of 
ursodeoxycholic acid has a positive impact on prognosis, 
none of the current models of treatment have shown a 
definitive impact on the natural history of PBC [16], and at 
the end stage of the disease, liver transplantation is the 
only effective mode of treatment [17].
Etiopathogenesis of PBC
Factors leading to PBC onset remain poorly understood, 
but  several  lines  of  evidence  suggest  that  immune­
mediated  mechanisms  play  a  crucial  role.  Numerous 
similarities  exist  between  PBC  and  other  autoimmune 
disorders,  including  female  predominance,  increased 
prevalence in subjects with a family history of PBC, and 
frequent  coexistence  with  other  autoimmune  diseases. 
The tissue selectivity of the immune attack is particular 
to  PBC,  as  is  the  poor  responsiveness  of  patients  to 
immune  suppression.  In  addition,  the  breakdown  of 
immune  tolerance  against  mitochondrial  and  nuclear 
self­antigens is also unique to PBC.
Cholangiocytes  play  an  important  role  in  the 
pathogenesis of PBC and may account for the high tissue 
specificity. Indeed, the PBC paradox is that the damage is 
highly localized and only targets the lining of the small 
and  medium­sized  intrahepatic  bile  ducts,  despite 
ubiquitous expression of the autoantigens [18]. The most 
recent data on apoptosis may provide the key to these 
observations [19]. Ultimately, the onset of PBC requires 
two components: a permissive genetic background and 
an  environmental  trigger.  While  the  discussion  of  this 
latter aspect goes beyond the aims of the present article 
[20], we will now review the numerous studies that asso­
ciate PBC onset with genetic variants and polymorphisms.
Putative genomic associations in PBC
PBC is more frequent in relatives of affected individuals, 
and the term ‘familial PBC’ has been coined to indicate 
families that have more than one case. Variable rates of 
familial PBC are seen in different geographical regions, 
possibly due to different methods of case definition. In 
general, data indicate that 1 to 6% of PBC cases have at 
least  one  other  family  member  presenting  with  the 
disease [21]. Such familial prevalence rates are signifi­
cantly higher than general population prevalence esti­
mates,  thus  indicating  a  genetic  predisposition  to  the 
disease. However, the difficulty of evaluating these data 
is  that  prevalence  rates  in  the  general  population  are 
still  uncertain  and  control  groups  are  not  always 
included  in  family  studies.  The  concordance  rate 
observed  among  monozygotic  twins  for  PBC  is  63%, 
among  the  highest  reported  in  auto  immune  diseases. 
This  reinforces  the  concept  of  an  important  genetic 
factor  in  susceptibility  to  this  disease  [21],  but  also 
highlights the necessity for an environmental insult, be 
it chemical, bacterial, or viral [22].
Several  studies  have  attempted  to  identify  the  genes 
associated with PBC. No family study of genetic linkage 
has been performed, possibly because PBC is a relatively 
rare disease and it is therefore difficult to obtain DNA 
samples from a large number of representative families. 
All available studies were designed in a controlled cross­
sectional fashion, but were prone to multiple sampling 
errors  and  biases  caused  by  incorrect  estimations.  A 
multi­hit  genetic  model  seems  to  apply  to  PBC,  with 
different genetic variants conferring susceptibility (first 
hit) and others influencing disease progression (second 
hit). For this reason, most authors investigating genetic 
factors in PBC have studied their role in susceptibility to 
the disease (comparing allele and genotype frequencies in 
patients and controls), as well as in its severity (through 
the analysis of clinical characteristics of patients carrying 
different geno  types or alleles). No definitive association 
of PBC suscepti  bility or progression could be identified 
in these studies [23]. When an association was found, it 
has proved to be weak or limited to specific geographical 
regions. We note that this also applies to the study of the 
variants  of  major  histocompatibility  complex  (MHC; 
including type I, II, and III loci), in which, unlike most 
autoimmune diseases, reported associations were often 
weak [24] or limited to specific geographical areas [25]. 
Similar findings were also reported from the study of the 
genetic variants of immuno  modulatory molecules (such 
as chemokines, receptors), enzymes producing vasoactive 
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associations are summarized next.
Major histocompatibility complex and PBC
Strong associations with specific MHC human leukocyte 
antigen (HLA) alleles have been reported in many auto­
immune diseases, in some cases constituting the gold­
standard  for  the  diagnosis  of  otherwise  undetermined 
cases [26].
Studies performed on small cohorts of subjects (between 
21 and 75) have examined the association between HLA 
class I molecules and PBC susceptibility [27­33], but the 
conclusions of these early reports were affected by several 
major  flaws,  including  limited  statistical  power,  and 
technological  problems  for  an  accurate  allele  analysis. 
Nevertheless, our group reported that PBC is associated 
with  various  HLA­B  alleles  in  a  small  proportion  of 
patients [34]. It is possible that the positive association 
might be secondary to linkage disequilibrium. Based on 
the  available  data,  we  should  therefore  regard  PBC 
associations with HLA class I genes as weak.
The association of HLA class II alleles with PBC has 
been  widely  studied  in  Caucasian  and  Asian  patient 
cohorts. In studies from Germany, Spain, Sweden, and 
the United States, HLA-DR8 (DRB1*08) was found with 
significantly  higher  frequency  in  patients  with  PBC 
compared  to  controls;  cumulatively,  data  aggregation 
indicates that DR8 might constitute a risk factor for PBC 
among  Caucasians  [32,35­38].  In  2001,  data  from 
Newcastle,  UK  demonstrated  that  the  linkage  of 
DQA1*0401 and DR8-DQB1*0402 is associated with PBC 
progression and not susceptibility [39]. Other studies in 
non­British  European  populations  have  not  confirmed 
this association [30,33,34,40,41]. Moreover, other Euro­
pean  studies  suggested  significant  associations  of  PBC 
with DR3 [27,33] and DPB1*0301 [42], while the most 
recent  study  from  the  United  States  demonstrated  an 
association between the DRB1*08-DQA1*0401-DQB1*04 
haplotype and PBC, albeit in a minority of patients [38]. 
Finally, studies from Japan failed to provide a consistent 
picture of HLA class II associations with PBC [28,29,43]. 
Interestingly, in a large series of Italian patients with PBC 
and  controls,  we  observed  a  protective  effect  of  the 
DRB1*11 allele in PBC, which was later confirmed in a 
larger set of patients and controls along with a positive 
association with DRB1*08 [25].
In summary, we can conclude that the picture of HLA 
class II involvement in PBC is quite complex. We could 
assume  that,  similar  to  the  epidemiological  data,  the 
genetic background in PBC could be associated with a 
geographical pattern.
Data  from  association  studies  of  polymorphisms  of 
tumor  necrosis  factor  (TNF)­α  in  PBC  are  conflicting 
and  a  cautious  interpretation  is  encouraged  [44].  A 
polymorphism of the gene promoter region produces the 
more  frequent  variant  TNF1,  and  the  less  frequent 
variant TNF2 [45], with TNF2 associated with increased 
transcription [46­48]. The prevalence of the TNF2 allele 
was reportedly protective against PBC onset [49] while 
two  other  studies  independently  failed  to  detect  any 
difference in genotype distributions between patients and 
controls [50,51]. In the study from Tanaka and colleagues, 
heterozygous patients had a significantly worse prognosis 
compared to homozygous TNF1/TNF1 patients [50], as 
indicated by higher Mayo score value, currently the only 
validated  index  for  PBC  [52].  However,  a  study  from 
Newcastle, UK did not confirm this alleged association 
[51].  Similarly,  data  obtained  from  Scottish,  Brazilian, 
and  Chinese  patient  cohorts  with  PBC  [41,53,54],  and 
from  a  small  population  of  patients  undergoing  liver 
transplantation  for  end­stage  PBC  [55],  revealed  no 
association of TNF genotypes with disease susceptibility 
or onset.
High­throughput  novel  technologies  have  made  the 
study of single nucleotide polymorphisms (SNPs) of candi­
date genes the method of choice for association studies in 
PBC.  The  analysis  of  SNPs  can  define  the  linkage  of 
specific loci or neighboring regions with disease traits. We 
note  that,  in  addition  to  the  general  considera  tions 
expressed  above  on  the  choice  of  candidate  genes  and 
populations, the study of SNPs should be more focused on 
coding  variants  (that  is,  with  demonstrated  effects  on 
phenotype) of genes, although this might exclude other 
SNPs that are possibly in linkage disequilibrium with genes 
that are important for disease onset [56].
Non-MHC genes in PBC
Most  studies  of  SNPs  in  PBC  have  been  dedicated  to 
molecules involved in regulating the immune response, 
thus  hypothesizing  that  genomic  differences  at  these 
levels might confer susceptibility to the loss of tolerance 
or  to  an  aberrant  immune  response.  Based  on  the 
expression of cytotoxic T lymphocyte antigen­4 (CTLA-4) 
by T cells following activation and the regulatory effect of 
this  molecule  on  peripheral  T  cell  responses,  SNPs  of 
CTLA-4  were  suggested  as  factors  facilitating  the 
breakdown of tolerance. Accordingly, the coding 49A>G 
SNP was found associated with PBC in a large British 
study  [57]  and  in  77  Chinese  patients  with  PBC  [58], 
while a smaller study from Brazil failed to confirm the 
association [41]. Several studies were further dedicated 
to SNPs of interleukins (ILs), based on their critical role 
in the regulation of the immune response. Prompted by 
experimental data such as its dysregulated production by 
monocytes in PBC [59], SNPs of IL-1 were studied. First, 
a  study  from  the  UK  reported  a  significantly  higher 
frequency of the IL-1B*1,1 genotype in patients with PBC 
compared  to  controls.  The  difference  in  the  IL-1B*1,1 
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with  early­stage  disease,  thus  possibly  indicating  that 
IL-1 alleles might influence disease progression [39]. The 
lack  of  association  with  PBC  onset  was  also  inde  pen­
dently  confirmed  by  Hungarian  [60]  and  Chinese  [61] 
researchers.  The  latter  group,  however,  more  recently 
described an association of PBC with the IL1-RN intron 
genotype, comparing frequencies in 77 patients with PBC 
and  160  controls  [62].  Further,  based  on  experi  mental 
evidence of cytokine profiles and their involve  ment in the 
development of T helper 1 cell responses, SNPs of the 
promoter region of the IL-10 gene were also analyzed in 
patients  with  PBC  and  controls  [53,62,63].  Data  from 
Italian  and  Japanese  series  demonstrated  that  both 
groups presented a higher prevalence of the ­1082G/G 
genotype [63]. Such association was not confirmed in 77 
Chinese patients with PBC [61,62].
SNPs of the 1,25­dihydroxyvitamin D receptor (VDR) 
gene have been investigated in several studies, based on 
the  dual  role  of  vitamin  D  in  the  regulation  of  bone 
metabolism  and  inflammation.  Accelerated  bone  loss 
rates in patients with prolonged cholestasis (as in PBC) 
have been repeatedly reported, sometimes with conflict­
ing  results,  and  in  some  cases  with  less  than  rigorous 
experimental designs. A significant association between 
BsmII polymorphisms of VDR and PBC was reported in 
patients with PBC from Germany, Hungary, and China 
[60,64­66], while the proposed association with bone loss 
[67] was not reproduced [68]. We believe that differences 
in  the  VDR  gene  might  unravel  further  potential 
scenarios  to  help  explain  the  infrequency  of  PBC  in 
African­American  women  [69],  and  could  in  turn 
support  a  possible  role  for  sunlight  exposure  in  PBC 
onset. Although fascinating, this assumption remains a 
hypothesis, yet to be confirmed.
Molecules  responsible  for  bile  acid  transport  and 
excretion in the biliary tree have been obvious targets in 
the  search  for  genomic  determinants  of  PBC  onset. 
Interestingly, SNPs and mutation of ATP binding cassette 
(ABC) transporters involved in the secretion of bile from 
the  hepatocyte  [70]  have  been  associated  with  intra­
hepatic cholestasis of pregnancy  [71], somehow repro­
duc  ing  the  clinical  picture  observed  in  PBC.  Pauli­
Magnus  and  colleagues  [70]  have  carried  out  gene 
sequenc  ing to investigate the variants of genes coding for 
the two main ABC transporters, identifying 45 ABCB11 
and 46 ABCB4 variants, but found that no mutation was 
associated  with  PBC.  More  recently,  a  similar  lack  of 
association  data  was  reported  for  the  anion  exchanger 
gene SLC4A2 [72].
Prompted by the xenobiotic PBC theory [21], we also 
investigated whether genetic variants leading to different 
xenobiotic metabolism or transport might in turn account 
for  an  increased  risk  of  developing  the  disease.  We 
therefore  genotyped  several  polymorphisms  of  enzymes 
involved in the transport and metabolism of xenobiotics in 
169 patients with PBC and 225 healthy controls [73]. Data 
demonstrated that no polymorphism was associated with 
PBC  susceptibility,  while  a  weak  association  of  the 
cytochrome P450 CYP2E1 c2 allele with disease severity 
was observed in a small subgroup of patients.
Recent  studies  demonstrated  that  copy  number 
variations are found in patients with PBC, as in the case 
of an intragenic region on chromosome 4 called MER115. 
This was identified during investigation regarding micro­
bial agents using representational difference analysis [74]. 
The  observation  that  keratin  mutations  are  more 
frequently  encountered  in  PBC  cases  and  reflect  the 
disease phenotype [75] is also of note.
Genome-wide studies come of age
More  recently,  the  first  genome­wide  case­control 
association  study  was  reported  in  PBC  cases  from 
Canada and the US [76] and reported significant associa­
tions of PBC with IL-12A, IL-12RB2, and STAT4 poly­
morphisms. The study benefited from sufficient statistical 
power due to the inclusion of 536 patients with PBC and 
1,536 controls genotyped for over 300,000 SNPs, and has 
to be regarded as the current state­of­the­art study into 
the  genetic  basis  of  PBC,  although  new  and  more 
powerful  genotyping  tools  are  becoming  available.  The 
role  of  IL-12  was  most  recently  supported  by  experi­
mental  data  from  our  group  demonstrating  in  a  PBC 
animal model that the IL-12p40 gene is crucial to auto­
immunity development [77], thus proving an ideal link 
between genomic studies and disease pathogenesis, with 
potential therapeutic implications
The sex chromosome connection in PBC
Similar  to  other  autoimmune  diseases  commonly 
diagnosed  in  women  after  the  menopause  [78],  fetal 
microchimerism  has  been  suggested  in  PBC,  with  the 
hypothesis of higher prevalence of small amounts of fetal 
(paternal) DNA found in mothers with PBC [79]. First, it 
was suggested that the presence of fetal DNA in the liver 
of  affected  women  years  after  pregnancy  might 
predispose to PBC [80]; however, independent findings 
have not confirmed this hypothesis [81,82]. Genes on the 
X chromosome are critical to the maintenance of physio­
logical  sex  hormone  levels  and,  more  importantly,  of 
immune  responsiveness  [83].  Invernizzi  and  colleagues 
reported age­dependent enhanced monosomy X in the 
peripheral  white  blood  cells  of  women  with  PBC  [84], 
and later data suggested that the X chromosome loss is 
preferential  (that  is,  it  more  commonly  involves  the 
paternal or maternal chromosome) [85]. This observation 
seems to indicate a polygenic model for PBC, with an 
X­linked  major  locus  of  susceptibility  in  which  genes 
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is well represented in the recent literature on conditions 
characterized by major sex chromosome defects [87­90].
Is it prime time for epigenetics?
Studying the genetic basis of human diseases may yield 
direct  data;  however,  uncovering  the  genetic  causes  of 
diseases may not help in reversing the disease process 
itself.  In  contrast,  epigenetic  mechanisms  governing 
diseases  seem  more  malleable  than  genetic  sequences, 
and if causal epigenetic changes are uncovered, they may 
be  potentially  reversed  through  pharmacological  inter­
ventions or changing environmental stimuli [91]. There is 
an emerging efficacy for cancer treatments in the use of 
‘epigenetic  drugs’  that  inhibit  DNA  methylation  or 
histone deacetylation [92], so such strategies may be useful 
to treat other human diseases with epigenetic bases.
Studies on the epigenetics of autoimmunity have been 
limited to SLE and rheumatoid arthritis, while no data 
are currently available for PBC [93]. In 1997, Huang and 
colleagues [94] failed to observe significant differences in 
X chromosome inactivation in four monozygotic twins 
discordant for SLE, although only one fully inactivated 
gene (androgen receptor) was evaluated in this work. On 
the other hand, Richardson and colleagues [95] demon­
strated  DNA  hypomethylation  of  T  lymphocytes  of 
patients affected by SLE. In association with the reportedly 
higher  numbers  of  CD4+  lymphocytes  in  females  com­
pared  to  males  [96],  these  data  encouraged  further 
analysis  in  the  field.  Drugs  such  as  hydralazine  and 
procainamide inhibit T­cell DNA methylation and induce 
a  murine  lupus­like  syndrome  characterized  by  the 
presence  of  anti­double  strand  DNA  (anti­dsDNA) 
antibodies  and  glomerulonephritis  [97].  Recently,  the 
effect  of  methylation  on  single  molecules  was  demon­
strated; Oelke and colleagues [98] reported the similar in 
vitro behavior of SLE T cells and healthy T cells treated 
with  DNA  methylation  inhibitors.  In  particular,  both 
lymphocyte populations overexpressed CD70, leading to 
an  increased  production  of  IgG  [98].  Taken  together, 
these  findings,  obtained  in  a  different  yet  female­
predominant autoimmune disease such as SLE, support 
the potential role of epigenetics in PBC, as represented 
by microRNA data [99].
Concluding remarks and future developments
Following the review of the numerous published studies 
on  the  genomic  associations  in  PBC,  three  major 
questions  remain.  Firstly,  how  do  these  new  variants 
increase our understanding of the disease or lead to new 
insights  about  disease  pathogenesis,  treatment  or 
manage  ment? This constitutes possibly the most promi­
nent weakness of the available studies in PBC genetics, as 
the candidate genes were often chosen based on a weak 
background.  This  limitation  can  be  overtaken  with 
rigorous approaches based on solid associations, as in the 
case of IL-12. Second, how have these variants impacted 
on  other  autoimmune  diseases  with  a  genetic  compo­
nent?  While  other  autoimmune  diseases  cannot  be 
directly compared to PBC, the presence of similar genetic 
associations  between  them  is  likely,  as  in  the  case  of 
STAT4 in SLE and rheumatoid arthritis [100]. The third 
and  most  difficult  question  is  related  to  the  potential 
clinical  applications  of  these  variants  for  personalized 
medicine in PBC [101]. We suggest that only the inte­
gration of genomic data with findings from epigenetics 
and microRNA research [102], possibly through the use 
of antisense oligomers, will provide a pragmatic use for 
the gathered evidence.
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